A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease

• Status: Completed
• Trial end date: 2008-05-09

Summary

Study to evaluate the safety, tolerability, and pharmacodynamics of migalastat hydrochloride (HCl) (migalastat) in participants with Fabry disease.

• Phase: Phase 2

Details

• Lead Sponsor: Amicus Therapeutics